0.55
1.81%
0.0098
Handel nachbörslich:
.55
Entero Therapeutics Inc Aktie (ENTO) Neueste Nachrichten
AzurRx BioPharma Announces Results of Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency - Marketscreener.com
Entero Therapeutics faces Nasdaq delisting over meeting lapse By Investing.com - Investing.com Australia
Entero Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
Entero therapeutics CFO sells $465 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF - GlobeNewswire Inc.
ENTO (Entero Therapeutics) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
First Wave BioPharma, Inc. announced that it expects to receive $4 million in funding - Marketscreener.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - News & Insights
Entero Therapeutics faces financial obligations acceleration By Investing.com - Investing.com Nigeria
Entero Therapeutics faces financial obligations acceleration - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks
Entero finds lifeline in reverse merger with nano-immunoconjugate firm Journey - FirstWord Pharma
Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Entero, Journey to merge, creating oncology-focused biopharma By Investing.com - Investing.com Canada
Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - Marketscreener.com
Entero stock in focus amid reverse merger plans (ENTO:NASDAQ) - Seeking Alpha
Entero, Journey to merge, creating oncology-focused biopharma - Investing.com
Entero Therapeutics Announces Proposed Reverse Merger with - GlobeNewswire
Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform | ENTO Stock News - StockTitan
FIRST WAVE BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients - Marketscreener.com
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients - Marketscreener.com
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
How Are Things Looking For Entero Therapeutics Inc. (NASDAQ: ENTO) For The Short Term? - Stocks Register
Entero therapeutics CFO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Entero therapeutics CFO sells shares to cover tax obligations - Investing.com India
Entero Therapeutics Inc.’s Market Journey: Closing Weak at 0.42, Down -19.41 - The Dwinnex
Taking on analysts’ expectations and winning: Entero Therapeutics Inc. (ENTO) - SETE News
Potential Price Increase for Entero Therapeutics Inc. (ENTO) After Recent Insider Activity - Knox Daily
Market cap of Entero Therapeutics Inc. [ENTO] reaches 1.95M – now what? - The DBT News
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):